Agenus is an immunology company discovering and developing novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. We are a dedicated group of scientists, researchers, biotechnologists, physicians, and businesspeople working together toward one goal: to discover and develop therapies that can unleash the innate power of the body’s immune system to treat and potentially cure hard-to-treat cancers and other diseases.
Our product candidates are designed to work by educating and activating the body’s immune system for a precise and potent attack on cancer. Our strategy is to help unlock the potential of one of the most exciting breakthrough areas in cancer treatment in decades, and to develop single agent and combination immune-oncology therapies that can help save lives.
Our approaches are driven by three platform technologies, including:
• Our antibody platforms, including our proprietary Retrocyte Display™ and SECANT® technologies, and our antibody programs, including checkpoint modulators, or CPMs;
• Our heat shock protein (HSP)-based vaccines; and
• Our saponin-based vaccine adjuvants, principally our QS-21 Stimulon® adjuvant.
We are passionate about the work we do every day at Agenus to deliver on the promise of immuno-oncology. If you’re looking for an inspired environment, passionate colleagues, and a culture that nurtures learning, innovation and team success, we invite you to join us.
Pipeline
From advanced programs in late-stage development to our earlier pre-clinical candidates, Agenus and its partners continue to advance our groundbreaking technologies and product candidates closer to clinical practice and closer to delivering on our promise of treating cancers and infectious diseases.
Company Growth (employees)
Agenus was founded in 1994 and is headquartered in Lexington, US
Agenus Office Locations
Agenus has an office in Lexington
Lexington, US (HQ)
3 Forbes Rd
Agenus Data and Metrics
Agenus Financial Metrics
Agenus's revenue was reported to be $27 m in Q1, 2017
USD
Revenue (Q1, 2017) | 27 m |
Net income (Q1, 2017) | (17.1 m) |
EBIT (Q1, 2017) | (13.3 m) |
Market capitalization (21-Sep-2017) | 406.7 m |
Cash (31-Mar-2017) | 113.9 m |
Agenus's current market capitalization is $406.7 m.
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 3 m | 7 m | 24.8 m | 22.6 m |
Revenue growth, % | 129% | 256% | (9%) | |
EBIT | (25 m) | (43.3 m) | (80.7 m) | (107.5 m) |
EBIT margin, % | (820%) | (621%) | (325%) | (476%) |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 3.1 m | 1.6 m | 4 m | 6.4 m | 6.8 m | 6 m | 6.6 m | 4.4 m | 27 m |
R&D expense | 5.2 m | 5.3 m | 9.2 m | 24.8 m | 18.5 m | 5.8 m | 6.6 m | 4.4 m | 27 m |
General and administrative expense | 5.8 m | 4.9 m | 5.5 m | 8 m | 6.4 m | 9.2 m | 7.1 m | 8.1 m | 7.8 m |
Operating expense total | 11.1 m | 10.2 m | 14.7 m | 32.8 m | 24.9 m | 15 m | 13.7 m | 12.6 m | 34.7 m |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 27.4 m | 25.7 m | 136.7 m | 71.4 m |
Accounts Receivable | 1.2 k | 9.8 m | 11.4 m | |
Inventories | 95.7 k | 88.2 k | 88.2 k | |
Current Assets | 28.2 m | 42.7 m | 184.1 m | 91.3 m |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 48.3 m | 38.4 m | 79.3 m | 124.7 m | 184.1 m | 78.3 m | 73.4 m | 75.4 m | 113.9 m |
Accounts Receivable | 2.5 m | 4.1 m | 7.3 m | 10.2 m | 9.4 m | 10.3 m | 6.8 m | ||
Inventories | 95.7 k | 95.7 k | 88.2 k | 88.2 k | 88.2 k | 88.2 k | 88.2 k | 88.2 k | 87.5 k |
Current Assets | 67 m | 55.2 m | 85.2 m | 146.3 m | 208.9 m | 161.6 m | 136.1 m | 109.5 m | 138 m |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | (30.1 m) | (42.5 m) | (87.9 m) | (127 m) |
Depreciation and Amortization | 586.3 k | 1.6 m | 2 m | 4.9 m |
Accounts Receivable | 551.1 k | 1.2 k | (9.3 m) | (1.5 m) |
Inventories | 16 k | (95.7 k) | 7.5 k | 7.5 k |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | (8.4 m) | (16.5 m) | (18.7 m) | (59.2 m) | (13.1 m) | (31.8 m) | (28.3 m) | (40.8 m) | (17.1 m) |
Depreciation and Amortization | 589.4 k | 1 m | 445.5 k | 885.5 k | |||||
Accounts Receivable | 1.2 k | 1.2 k | (2.1 m) | (4 m) | 7.3 m | 10.2 m | 9.4 m | 10.3 m | 6.8 m |
Inventories | (95.7 k) | (95.7 k) | 7.5 k | 7.5 k | 88.2 k | 88.2 k | 88.2 k | 88.2 k | 87.5 k |
| USD | Y, 2017 |
|---|---|
Revenue/Employee | 111.2 k |
Financial Leverage | 22.8 x |
Agenus Market Value History
Agenus Median Salaries
Source: 15 public H-1B filings from Agenus
